SCHEMBL1607208

SCHEMBL1607208

CCc1ccc(O)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.52
TTR P02766 1/20 0.45
TYR P14679 3/20 0.44
BACE1 P56817 1/20 0.43
ESR1 P03372 5/20 0.42
ESR2 Q92731 4/20 0.42
HSD17B3 P37058 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX5 P09917 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9565680 0.83 TYR (0.50) HSD17B10TTRTYRESR1ESR2
SCHEMBL365736 0.82 HSD17B10 (0.52) HSD17B10TTRTYRESR1ESR2
SCHEMBL4208352 0.81 TYR (0.58) HSD17B10TTRTYRESR1ESR2
SCHEMBL6166403 0.81 HSD17B10 (0.56) HSD17B10TTRTYRBACE1ESR1
SCHEMBL3794781 0.81 MAPT (0.54) HSD17B10ESR1ESR2MAPTMEN1
SCHEMBL28065665 0.79 HSD17B10 (0.45) HSD17B10TTRBACE1CYP3A4
SCHEMBL11655822 0.79 TYR (0.67) HSD17B10TYRESR1ESR2MAPT
SCHEMBL696223 0.79 HSD17B10 (0.54) HSD17B10TTRTYRBACE1ESR1
SCHEMBL11329428 0.79 HSD17B10 (0.54) HSD17B10TTRTYRBACE1ESR1
SCHEMBL13318422 0.78 HSD17B10 (0.48) HSD17B10TTRTYRESR1HSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103249758-A Isosorbide-containing polycarbonates and their preparation SABIC INNOVATIVE PLASTICS IP 2013-08-14 CN claimed
CN-1938379-B Impact-modified compositions and methods GEN ELECTRIC 2012-05-16 CN claimed
CN-1976995-B Polyarylate compositions GEN ELECTRIC 2010-06-09 CN claimed
US-20100130784-A1 SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROPAN-2-OL COMPOUNDS PFIZER INC. 2010-05-27 US claimed
CN-100572349-C Method for purifying 1, 1-bis (4 '-hydroxy-3' -methylphenyl) cyclohexane and method for producing polycarbonate therefrom GEN ELECTRIC (NL) 2009-12-23 CN claimed
CN-100554332-C The goods that polycarbonate molding compositions and specious degree thereof improve GEN ELECTRIC (NL) 2009-10-28 CN claimed
CN-100535029-C Method for producing copolyestercarbonates GEN ELECTRIC (NL) 2009-09-02 CN claimed
CN-101374908-A Foamed and foamable high glass transition temperature polymers GEN ELECTRIC (US) 2009-02-25 CN claimed
CN-101370873-A Annular or tubular shaped articles of novel polymer blends GEN ELECTRIC (US) 2009-02-18 CN claimed
CN-101370872-A Food service articles of manufacture comprising high temperature polymers GEN ELECTRIC (US) 2009-02-18 CN claimed
US-6451830-B1 Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. 2002-09-17 US claimed
US-6448295-B1 TREATING CARDIOVASCULAR DISEASE; ATHEROSCLEROSIS, DYSLIPIDEMA HYPERCHOLESTEROLAEMIA; DECREASING CONCENTRATIONS OF LOW DENSITY LIPOPROTEIN AND RAISING LEVEL OF HIGH DENSITY LIPOPROTEIN G.D. SEARLE & CO. 2002-09-10 US claimed
US-20020120011-A1 Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity SIKORSKI JAMES A (US) 2002-08-29 US claimed
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. (US) 2001-08-30 US claimed
EP-1115695-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(N+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
EP-1115693-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
EP-1115694-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
WO-2000018723-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-2000018724-A1 (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-2000018721-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity CETP, DBI, MTTP HSD17B10 422/4885TTR 248/4885TYR 2475/4885
US-20100130784-A1 SUBSTITUTED 1,1,1-TRIFLUORO-3-[(BENZYL)-(PYRIMIDIN-2-YL)-AMINO]-PROPAN-2-OL COMPOUNDS APOB, LDLR, HDLBP HSD17B10 941/4885TTR 41/4885TYR 1266/4885
US-20020120011-A1 Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity CETP, PCTP, DBI HSD17B10 1281/4885TTR 1355/4885TYR 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.